Core Viewpoint - The company is developing innovative small molecule drugs for the treatment of Respiratory Syncytial Virus (RSV) infections, as there are currently no specific treatment options available in the domestic market [1] Group 1: Company Developments - The company has initiated a project focused on small molecule drugs targeting RSV, demonstrating strong antiviral activity against multiple RSV strains, excellent pharmacokinetic properties, and low toxicity [1] - The RSV project is currently in the preclinical research stage, with plans for orderly advancement in development [1] Group 2: Product Information - The company's drug, Angladiwei Tablets (brand name: Anruiwei®), is indicated for the treatment of uncomplicated influenza A in adults, with a recommendation for professional medical guidance on usage [1]